Shanghai Haohai Biological Technology Co., Ltd.
シンボルマーク: 6826.HK
HKSE
42.45
HKD今日の市場価格
15.1027
PER(株価収益率
0.7575
PEGレシオ
16.43B
MRK キャップ
- 0.01%
DIV利回り
Shanghai Haohai Biological Technology Co., Ltd. (6826-HK) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 2751.1 | 2541.7 | 2907.2 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 11.1 | 6.7 | 6.4 | ||||||||||
balance-sheet.row.net-receivables | 0 | 447.6 | 471.1 | 375.2 | ||||||||||
balance-sheet.row.inventory | 0 | 526.2 | 485.2 | 354.8 | ||||||||||
balance-sheet.row.other-current-assets | 0 | 25.2 | 34.1 | 69.6 | ||||||||||
balance-sheet.row.total-current-assets | 0 | 3750.1 | 3532.1 | 3712.6 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1553 | 1409.6 | 1248.9 | ||||||||||
balance-sheet.row.goodwill | 0 | 413 | 411.2 | 406.9 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 729.1 | 783.5 | 783.1 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1142.1 | 1194.7 | 1190 | ||||||||||
balance-sheet.row.long-term-investments | 0 | 596 | 664.7 | 619 | ||||||||||
balance-sheet.row.tax-assets | 0 | 53.1 | 59.3 | 49.4 | ||||||||||
balance-sheet.row.other-non-current-assets | 0 | 11.1 | 32 | 130.5 | ||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3355.4 | 3360.3 | 3237.8 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 0 | 7105.5 | 6892.4 | 6950.4 | ||||||||||
balance-sheet.row.account-payables | 0 | 55.1 | 54.5 | 46.3 | ||||||||||
balance-sheet.row.short-term-debt | 0 | 216.6 | 34.4 | 66 | ||||||||||
balance-sheet.row.tax-payables | 0 | 58.4 | 52.1 | 17.8 | ||||||||||
balance-sheet.row.long-term-debt-total | 0 | 191.3 | 83.9 | 39.5 | ||||||||||
Deferred Revenue Non Current | 0 | 13.6 | 5.5 | 9.4 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 0 | 444.2 | 422.4 | 375 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 372.3 | 478.7 | 402.8 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 54.2 | 61.3 | 46.7 | ||||||||||
balance-sheet.row.total-liab | 0 | 1088.2 | 990 | 890.1 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 71.7 | 47 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 171.5 | 174.1 | 175.8 | ||||||||||
balance-sheet.row.retained-earnings | 0 | 2728.6 | 2369.5 | 2309.7 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -71.7 | -47 | 47.9 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2750 | 2971 | 3180 | ||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 5650.1 | 5514.6 | 5713.5 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 7105.5 | 6892.4 | 6950.4 | ||||||||||
balance-sheet.row.minority-interest | 0 | 367.2 | 387.8 | 346.8 | ||||||||||
balance-sheet.row.total-equity | 0 | 6017.3 | 5902.4 | 6060.3 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||
Total Investments | 0 | 607.1 | 671.4 | 625.3 | ||||||||||
balance-sheet.row.total-debt | 0 | 407.9 | 118.3 | 105.5 | ||||||||||
balance-sheet.row.net-debt | 0 | -2332.1 | -2423.5 | -2795.3 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 508.3 | 235.7 | 382.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 197.9 | 204.2 | 162.8 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | -81.6 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 14.3 | 30.2 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | 0 | 73.2 | -183.5 | 23.9 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | -52.3 | -41.9 | ||||||||||
cash-flows.row.inventory | 0 | -48.4 | -138.9 | -28.6 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 52.3 | 41.9 | ||||||||||
cash-flows.row.other-working-capital | 0 | 121.6 | -44.6 | 52.6 | ||||||||||
cash-flows.row.other-non-cash-items | 0 | -77.6 | -55.4 | -227.1 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -267.2 | -317.1 | -272.1 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 1.6 | 14.7 | -83.3 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | -204.2 | -528.8 | -696.6 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 14.6 | 9.1 | 749.3 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 78.6 | 140.4 | 154.6 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -376.6 | -681.8 | -148.1 | ||||||||||
cash-flows.row.debt-repayment | 0 | -16.4 | -47.9 | -95.5 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 73.7 | 0 | -4 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | -270 | -147.7 | -44.9 | ||||||||||
cash-flows.row.dividends-paid | 0 | -68.5 | -121.9 | -87.9 | ||||||||||
cash-flows.row.other-financing-activites | 0 | -245.7 | 29.1 | 1.1 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -257.7 | -288.4 | -231.3 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 10 | 14.2 | -6.9 | ||||||||||
cash-flows.row.net-change-in-cash | 0 | 10.1 | -724.7 | -44 | ||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 569.3 | 559.2 | 1283.9 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 559.2 | 1283.9 | 1327.9 | ||||||||||
cash-flows.row.operating-cash-flow | 0 | 634.5 | 231.3 | 342.3 | ||||||||||
cash-flows.row.capital-expenditure | 0 | -267.2 | -317.1 | -272.1 | ||||||||||
cash-flows.row.free-cash-flow | 0 | 367.2 | -85.9 | 70.2 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 2634.9 | 2103.4 | 1750.1 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 781.4 | 656.5 | 490.4 | ||||||||||
income-statement-row.row.gross-profit | 0 | 1853.5 | 1446.9 | 1259.7 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | -4 | -40.3 | -33.9 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 1415.1 | 1226.8 | 1032.2 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 2196.5 | 1883.3 | 1522.5 | ||||||||||
income-statement-row.row.interest-income | 0 | 77.7 | 87.9 | 98.2 | ||||||||||
income-statement-row.row.interest-expense | 0 | 7.3 | 7.6 | 5 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -4.7 | -22.9 | -1.8 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | -4 | -40.3 | -33.9 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | -4.7 | -22.9 | -1.8 | ||||||||||
income-statement-row.row.interest-expense | 0 | 7.3 | 7.6 | 5 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 197.9 | 204.2 | 162.8 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | 513 | 258.7 | 384.4 | ||||||||||
income-statement-row.row.income-before-tax | 0 | 508.3 | 235.7 | 382.6 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 96 | 45.4 | 35.4 | ||||||||||
income-statement-row.row.net-income | 0 | 416.1 | 180.5 | 352.2 |
よくある質問
Shanghai Haohai Biological Technology Co., Ltd.6826.HK 総資産とは何ですか?
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) 総資産は 7105497000.000.
企業の年間売上高とは?
年間収益は N/Aである.
企業の利益率は?
利益率は 0.698 である.
企業のフリーキャッシュフローとは?
フリーキャッシュフローは 1.049.
企業の純利益率は?
純利益率は 0.162 である.
企業の総収入は?
総収入は 0.177 である.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) 純利益(純利益)とは何ですか?
純利益(純利益)は 416121000.000.
負債総額は?
負債合計は 407949000.000 である.
営業費用はいくらですか?
営業費用は 1415132000.000 である.
会社の現金はいくらですか?
企業の現金は 0.000 である.